Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526684 | 0.81 | TSHR (0.47) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL2653650 | 0.80 | TRPA1 (0.46) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL41854 | 0.79 | TSHR (0.45) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL30407772 | 0.78 | GABRA1 (0.58) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL5496813 | 0.78 | GABRA1 (0.58) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL8784146 | 0.78 | TSHR (0.50) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL30337376 | 0.78 | TSHR (0.50) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL19468131 | 0.78 | TSHR (0.50) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL1945388 | 0.78 | TSHR (0.50) | TSHRACHEGABRA1GABRB2ALDH1A1 | |
| SCHEMBL542212 | 0.78 | GABRA1 (0.58) | TSHRACHEGABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150793-A1 | POLYCRYSTALLINE FORM OF BIPHENOL DIGLYCIDYL ETHER, AND RESIN COMPOSITION CONTAINING SAID POLYCRYSTALLINE FORM AND CURED PRODUCT THEREOF | 三菱ケミカル株式会社 | 2024-07-18 | — | — | WO | disclosed |
| CN-118055961-A | Method for producing epoxy resin, epoxy resin composition, cured product, and electric/electronic component | 三菱化学株式会社 | 2024-05-17 | — | — | CN | disclosed |
| CN-117957264-A | Resin composition, cured product, resin sheet, insulating layer, electric/electronic component, printed wiring board, and curing agent for epoxy resin | 三菱化学株式会社 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024071129-A1 | ACTIVE ESTER RESIN, EPOXY RESIN COMPOSITION AND CURED PRODUCT THEREOF, PREPREG, LAMINATED BOARD, AND BUILD-UP FILM | 日鉄ケミカル＆マテリアル株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-11807711-B2 | Phenoxy resin, resin composition including same, cured object obtained therefrom, and production method therefor | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2023-11-07 | — | — | US | disclosed |
| CN-116075529-A | Method for producing aromatic ether compound having vinyl group | 日铁化学材料株式会社 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023053875-A1 | MODIFIED EPOXY RESIN, RESIN COMPOSITION, CURED OBJECT, LAMINATE FOR ELECTRICAL/ELECTRONIC CIRCUIT, AND METHOD FOR PRODUCING MODIFIED EPOXY RESIN | 日鉄ケミカル＆マテリアル株式会社 | 2023-04-06 | — | — | WO | disclosed |
| US-20230097650-A1 | ACTIVE ESTER RESIN, METHOD FOR PRODUCING THEREOF, EPOXY RESIN COMPOSITION, CURED PRODUCT THEREOF, PREPREG, LAMINATED BOARD, AND MATERIAL FOR CIRCUIT SUBSTRATE | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| WO-2023048209-A1 | RESIN COMPOSITION, CURED PRODUCT, RESIN SHEET, INSULATION LAYER, ELECTRIC/ELECTRONIC COMPONENT, PRINTED CIRCUIT BOARD, AND CURING AGENT FOR EPOXY RESIN | 三菱ケミカル株式会社 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023042650-A1 | MODIFIED EPOXY RESIN, RESIN COMPOSITION, CURED ARTICLE, LAMINATED BOARD FOR ELECTRIC/ELECTRONIC CIRCUITS, AND METHOD FOR PRODUCING MODIFIED EPOXY RESIN | 日鉄ケミカル＆マテリアル株式会社 | 2023-03-23 | — | — | WO | disclosed |
| US-20030027902-A1 | Piperazinone derivatives | LAZZARI DARIO (IT) | 2003-02-06 | — | — | US | disclosed |
| WO-2001062739-A2 | THIOIMIDAZOLIDINE DERIVATIVES AS LIGHT STABILIZERS FOR POLYMERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-08-30 | — | — | WO | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0700390-B1 | INTERMEDIATES AND METHODS FOR THE SYNTHESIS OF ANTHRAPYRAZOLONE ANTICANCER AGENTS | DU PONT MERCK PHARMA (US) | 1998-11-18 | — | — | EP | disclosed |
| US-5618944-A | Method for the synthesis of anthrapyrazolones | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0700390-A1 | INTERMEDIATES AND METHODS FOR THE SYNTHESIS OF ANTHRAPYRAZOLONE ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5393886-A | Intermediates for the synthesis of anthrapyrazolone anticancer agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1994025441-A1 | INTERMEDIATES AND METHODS FOR THE SYNTHESIS OF ANTHRAPYRAZOLONE ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-10 | — | — | WO | disclosed |
| US-4871757-A | PESTICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027902-A1 | Piperazinone derivatives | H1-4, EIF4G1, GPX4 | TSHR 4191/4885ACHE 3825/4885GABRA1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.